Cargando…
The Role and Therapeutic Targeting of CCR5 in Breast Cancer
The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, rece...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526962/ https://www.ncbi.nlm.nih.gov/pubmed/37759462 http://dx.doi.org/10.3390/cells12182237 |
_version_ | 1785111105614381056 |
---|---|
author | Hamid, Rasha Alaziz, Mustafa Mahal, Amanpreet S. Ashton, Anthony W. Halama, Niels Jaeger, Dirk Jiao, Xuanmao Pestell, Richard G. |
author_facet | Hamid, Rasha Alaziz, Mustafa Mahal, Amanpreet S. Ashton, Anthony W. Halama, Niels Jaeger, Dirk Jiao, Xuanmao Pestell, Richard G. |
author_sort | Hamid, Rasha |
collection | PubMed |
description | The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, recent studies have shown the induction of CCR5 on the surface of breast cancer epithelial cells. The function of CCR5 on breast cancer epithelial cells includes the induction of aberrant cell survival signaling and tropism towards chemo attractants. As CCR5 is not expressed on normal epithelium, the receptor provides a potential useful target for therapy. Inhibitors of CCR5 (CCR5i), either small molecules (maraviroc, vicriviroc) or humanized monoclonal antibodies (leronlimab) have shown anti-tumor and anti-metastatic properties in preclinical studies. In early clinical studies, reviewed herein, CCR5i have shown promising results and evidence for effects on both the tumor and the anti-tumor immune response. Current clinical studies have therefore included combination therapy approaches with checkpoint inhibitors. |
format | Online Article Text |
id | pubmed-10526962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105269622023-09-28 The Role and Therapeutic Targeting of CCR5 in Breast Cancer Hamid, Rasha Alaziz, Mustafa Mahal, Amanpreet S. Ashton, Anthony W. Halama, Niels Jaeger, Dirk Jiao, Xuanmao Pestell, Richard G. Cells Review The G-protein-coupled receptor C-C chemokine receptor 5 (CCR5) functions as a co-receptor for the entry of HIV into immune cells. CCR5 binds promiscuously to a diverse array of ligands initiating cell signaling that includes guided migration. Although well known to be expressed on immune cells, recent studies have shown the induction of CCR5 on the surface of breast cancer epithelial cells. The function of CCR5 on breast cancer epithelial cells includes the induction of aberrant cell survival signaling and tropism towards chemo attractants. As CCR5 is not expressed on normal epithelium, the receptor provides a potential useful target for therapy. Inhibitors of CCR5 (CCR5i), either small molecules (maraviroc, vicriviroc) or humanized monoclonal antibodies (leronlimab) have shown anti-tumor and anti-metastatic properties in preclinical studies. In early clinical studies, reviewed herein, CCR5i have shown promising results and evidence for effects on both the tumor and the anti-tumor immune response. Current clinical studies have therefore included combination therapy approaches with checkpoint inhibitors. MDPI 2023-09-08 /pmc/articles/PMC10526962/ /pubmed/37759462 http://dx.doi.org/10.3390/cells12182237 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hamid, Rasha Alaziz, Mustafa Mahal, Amanpreet S. Ashton, Anthony W. Halama, Niels Jaeger, Dirk Jiao, Xuanmao Pestell, Richard G. The Role and Therapeutic Targeting of CCR5 in Breast Cancer |
title | The Role and Therapeutic Targeting of CCR5 in Breast Cancer |
title_full | The Role and Therapeutic Targeting of CCR5 in Breast Cancer |
title_fullStr | The Role and Therapeutic Targeting of CCR5 in Breast Cancer |
title_full_unstemmed | The Role and Therapeutic Targeting of CCR5 in Breast Cancer |
title_short | The Role and Therapeutic Targeting of CCR5 in Breast Cancer |
title_sort | role and therapeutic targeting of ccr5 in breast cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526962/ https://www.ncbi.nlm.nih.gov/pubmed/37759462 http://dx.doi.org/10.3390/cells12182237 |
work_keys_str_mv | AT hamidrasha theroleandtherapeutictargetingofccr5inbreastcancer AT alazizmustafa theroleandtherapeutictargetingofccr5inbreastcancer AT mahalamanpreets theroleandtherapeutictargetingofccr5inbreastcancer AT ashtonanthonyw theroleandtherapeutictargetingofccr5inbreastcancer AT halamaniels theroleandtherapeutictargetingofccr5inbreastcancer AT jaegerdirk theroleandtherapeutictargetingofccr5inbreastcancer AT jiaoxuanmao theroleandtherapeutictargetingofccr5inbreastcancer AT pestellrichardg theroleandtherapeutictargetingofccr5inbreastcancer AT hamidrasha roleandtherapeutictargetingofccr5inbreastcancer AT alazizmustafa roleandtherapeutictargetingofccr5inbreastcancer AT mahalamanpreets roleandtherapeutictargetingofccr5inbreastcancer AT ashtonanthonyw roleandtherapeutictargetingofccr5inbreastcancer AT halamaniels roleandtherapeutictargetingofccr5inbreastcancer AT jaegerdirk roleandtherapeutictargetingofccr5inbreastcancer AT jiaoxuanmao roleandtherapeutictargetingofccr5inbreastcancer AT pestellrichardg roleandtherapeutictargetingofccr5inbreastcancer |